Clinical Trial Update: Treg Modulation With CD28 and IL-6 Receptor Antagonists [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trials evaluating regulatory T cell modulation using CD28 and IL-6 receptor antagonists in kidney transplant recipients have completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CD28 modulator for regulatory T cell modulation
• Interleukin-6 receptor antagonist

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Living-Donor Kidney Transplant, Kidney Transplant Recipients | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-09